(Finance) – Svas Biosanaa company listed on Euronext Growth Milan and active in the production of medical devices for healthcare facilities, closed 2023 with revenues from core management equal to 118.3 million euros, with an increase of +21.7% YoY compared to 31 December 2022. TheEBITDA amounts to 14.2 million euros, an increase of 19.7%, with an EBITDA margin of 12.0% on revenues. L’Net income it is positive for 5.1 million euros, an increase of 43.5%.
“We are very satisfied of the results for the 2023 financial year, the best ever, which further consolidate the Group’s market position, confirming a now structural growth – commented theAD Umberto Perillo – Careful management, investments to improve productivity and the focus on the quality of products and services have allowed us to obtain the excellent results of which we are proud, despite the increase in the costs of production factors. The goal is to continue investing in innovation in order to provide our customers with increasingly effective solutions.”
There Net Financial Position it is cash negative for 23.8 million euros, an improvement compared to the cash negative NFP of 25.2 million at 30 June 2023.
The Board of Directors approved the distribution of a dividend of 0.30 euros for each share that will be in circulation on the ex-dividend date (net of treasury shares that will be in the portfolio on that date) according to the following dates: ex-dividend date 27 May 2024, record date 28 May 2024, payment dates May 29, 2024.